The EPS beat is marginal and the post-quarter dilutive offering offsets any positive read-through from the pipeline update. Monitor for further clinical data readouts from the Phase 1 oncology study and any additional financing needs, as the company's cash runway is limited.
Price Chart
Executive Summary
Aethlon Medical reported Q1 FY2027 EPS of -$4.02, slightly beating the -$4.05 consensus estimate, with operating expenses down 11.9% YoY. The company dosed the first participant in the final cohort of its Phase 1 oncology study and raised ~$4M post-quarter to extend its cash runway. For a $2M market cap clinical-stage company, the EPS beat is marginal and the stock's movement will depend on sentiment around the early-stage pipeline progress and the dilutive offering.
Key Financial Metrics
Key Facts
- EPS of -$4.02 beat consensus of -$4.05 by 0.7%
- Operating expenses decreased 11.9% YoY to ~$1.6M
- Cash and equivalents were ~$4.9M as of June 30, 2026
- Raised ~$4.0M in gross proceeds from a public offering post-quarter
- First participant dosed in the third and final cohort of the Phase 1 oncology study in Australia
- Net loss per share improved from -$42.42 to -$4.02 due to a large increase in weighted average shares outstanding
Financial Impact
EPS beat of 0.7% is negligible; operating loss improved by ~12% YoY; post-quarter $4M offering provides ~12 months of cash runway
Risk Factors
- Clinical-stage company with no approved products or revenue; high cash burn rate
- Post-quarter dilutive public offering increases share count and dilutes existing holders
- Nasdaq listing compliance risk given low market cap and stock price
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302850290 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | SC 13G | $5.05 $5.07 | ▲ +0.40% | ▼ −0.06% | $5.15 (+1.98%) |
Oct 1, 2026 25d ago | 8-K | $6.45 $6.05 | ▲ +6.20% | ▲ +7.36% | $5.15 (+20.16%) |
Sep 17, 2026 5w ago | 425 | $6.78 $6.77 | ▼ −0.15% | ▼ −0.75% | $5.15 (−24.04%) |
Sep 17, 2026 5w ago | 8-K | $6.78 $6.77 | ▼ −0.15% | ▼ −0.75% | $5.15 (−24.04%) |
Sep 15, 2026 5w ago | 8-K | $1.47 $6.31 | ▲ +329.25% | ▲ +328.43% | $5.15 (+250.34%) |
Sep 4, 2026 7w ago | DEFA14A | $1.81 $1.47 | ▲ +18.78% | ▲ +17.67% | $5.15 (−184.53%) |
Aug 31, 2026 8w ago | 8-K | $2.06 $1.81 | ▼ −12.14% | ▼ −11.99% | $5.15 (+150.00%) |
Aug 13, 2026 10w ago | Press Release | $2.83 $2.73 | ▼ −3.53% | ▼ −2.17% | $5.15 (+81.98%) |
Jul 31, 2026 12w ago | 8-K | $0.6628 $0.6300 | ▲ +4.95% | ▲ +8.46% | $5.15 (−677.01%) |
Jul 7, 2026 16w ago | EFFECT | $0.7297 $0.6850 | ▲ +6.13% | ▲ +6.68% | $5.15 (−605.77%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers